Digital therapeutics (DTx) were gaining popularity as tools to help slash the US’ $3 trillion annual spending on chronic disease, and the pandemic has vaulted digital therapies into the spotlight. Now, the Teladoc-Livongo megamerger is heating up competition in the DTx space as players race to capture a slice of a market slated to reach $56 billion by 2025.
Here are the three key questions this report will answer:
WHAT’S IN THIS REPORT? In this report, Insider Intelligence unpacks the state of the digital therapeutics (DTx) market. We explore the impact the $18.5 billion Teladoc-Livongo merger has had on competition in the virtual care space, and how the pandemic has catapulted the global DTx market to reach $56 billion over the next five years. We outline the top DTx startups that are ripe for tie-ups, and provide examples of how payers, pharma, and telehealth vendors should benefit from partnering with or acquiring a DTx firm. Finally, we highlight the barriers that are holding back wide-scale adoption of digital therapeutics.
Exportable files for easy reading, analysis and sharing.
One Liberty Plaza9th FloorNew York, NY 100061-800-405-0844